Posts

Daiichi Sankyo Targets Nearly $15B in Oncology Sales by 2030 via ADC Franchise Expansion

on
Daiichi Sankyo aims for almost $15B in oncology sales by 2030, driven by its ADC franchise to surpass 3 trillion JPY ($19B) total revenues. ADC market projected to grow at ~25% CAGR to $10B by 2025 and $15B by 2030 per Grand View Research. Key pipeline includes Enhertu (~$4.3B FY25 risk-adjusted, ~$8.3B FY29e), DS-1062 (~$712M FY25), U3-1402 (~$680M FY25), DS-7300 (~$140M FY25). Enhertu and Padcev represent 2 of 9 globally approved ADCs from Japan. Merck's $22B Daiichi Sankyo ADC deal (2023) targets solid tumors, supporting franchise growth. Sources:

FibroBiologics Advances Fibroblast Platform for Hantavirus Pulmonary Syndrome Treatment

on

CSL Takes $5B Impairment Charge and Revenue Cut

on

Inhibrx's OX40 Agonist INBRX-106 Doubles Tumor Response Rate with Keytruda in Head and Neck Cancer Trial

on

Argenx's Vyvgart and Vyvgart Hytrulo Receive FDA Label Expansion for All Adult gMG Patients

on

Astellas Highlights Positive Early Data from Stem Cell-Derived RPE Therapy for Geographic Atrophy

on

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

on

Trump Reportedly Planning to Fire FDA Commissioner Marty Makary

on

FDA Approves Bizengri (Zenocutuzumab) for NRG1 Fusion-Positive Cholangiocarcinoma, First Targeted Therapy for Ultra-Rare Bile Duct Cancer

on

Access to Apps Reshaping Healthcare in Shandong

on

Why AI's Top Young Talent Isn't Interested in Careers at Big Drugmakers

on

Daiichi Sankyo's ADC Manufacturing Investments and Market Position

on

Odyssey Therapeutics Secures $279M IPO Amid Biotech Funding Challenges

on